English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

DDIT4  gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several  in vitro  studies indicate that its expression favors cancer progression. We have previously described that  DDIT4  expression is an independent prognostic factor for tripe negative breast cancer resistant to neoadjuvant chemotherapy. We herein report that high  DDIT4  expression is related to the outcome (recurrence-free survival, time to progression and overall survival) in several cancer types. We performed  in silico  analysis in online platforms, in pooled datasets from KM Plotter and meta-analysis of individual datasets from SurvExpress. High levels of  DDIT4  were significantly associated with a worse prognosis in acute myeloid leukemia, breast cancer, glioblastoma multiforme, colon, skin and lung cancer. Conversely, a high  DDIT4  expression was associated with an improved prognostic in gastric cancer.  DDIT4  was not associated with the outcome of ovarian cancers. Analysis with data from the Cell Miner Tool in 60 cancer cell lines indicated that although rapamycin activity was correlated with levels of  MTOR , it is not influenced by  DDIT4  expression. In summary,  DDIT4  might serve as a novel prognostic biomarker in several malignancies.  DDIT4  activity could be responsible for resistance to mTOR inhibitors and is a potential candidate for the development of targeted therapy.

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies